Cargando…
Tau Phosphorylation, Aggregation, and Cell Toxicity
Protein aggregation takes place in many neurodegenerative disorders. However, there is a controversy about the possible toxicity of these protein aggregates. In this review, this controversy is discussed, focussing on the tau aggregation that takes place in those disorders known as tauopathies.
Autores principales: | Avila, J., Santa-María, I., Pérez, M., Hernández, F., Moreno, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1479889/ https://www.ncbi.nlm.nih.gov/pubmed/17047313 http://dx.doi.org/10.1155/JBB/2006/74539 |
Ejemplares similares
-
Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
por: Santa-Maria, Ismael, et al.
Publicado: (2007) -
Suppressing Tau Aggregation and Toxicity by an Anti-Aggregant Tau Fragment
por: Pir, Ghulam Jeelani, et al.
Publicado: (2018) -
Toxic tau: structural origins of tau aggregation in Alzheimer's disease
por: Mamun, Abdullah Al, et al.
Publicado: (2020) -
Are Tau Aggregates Toxic or Protective in Tauopathies?
por: Cowan, Catherine M., et al.
Publicado: (2013) -
Tau Phosphorylation by GSK3 in Different Conditions
por: Avila, Jesús, et al.
Publicado: (2012)